1. Home
  2. BW vs GYRE Comparison

BW vs GYRE Comparison

Compare BW & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Babcock & Wilcox Enterprises Inc.

BW

Babcock & Wilcox Enterprises Inc.

HOLD

Current Price

$8.84

Market Cap

919.9M

Sector

Industrials

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$8.33

Market Cap

759.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BW
GYRE
Founded
1867
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Building Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
919.9M
759.1M
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
BW
GYRE
Price
$8.84
$8.33
Analyst Decision
Buy
Strong Buy
Analyst Count
3
2
Target Price
$7.00
$17.00
AVG Volume (30 Days)
2.2M
58.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
103.55
EPS
N/A
0.04
Revenue
N/A
$275,000.00
Revenue This Year
N/A
$11.59
Revenue Next Year
$6.69
$26.31
P/E Ratio
N/A
$214.38
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$6.11
52 Week High
$11.57
$13.47

Technical Indicators

Market Signals
Indicator
BW
GYRE
Relative Strength Index (RSI) 47.58 53.69
Support Level $7.98 $6.94
Resistance Level $11.57 $9.31
Average True Range (ATR) 0.76 0.37
MACD -0.17 0.03
Stochastic Oscillator 26.43 48.89

Price Performance

Historical Comparison
BW
GYRE

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: